Browsing by Subject "CANCER"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Analyses Of Detoxification And DNA Damage From The Human Carcinogens Benzene And N′-Nitrosonornicotine
    (2016-04) Casemore, Denise
    The Xing lab has explored CXL compounds as cytotoxic anticancer agents in multi-drug resistant leukemic cell lines. CXL compounds have exhibited an increased potency in drug resistant cell lines compared to their parental cell lines. CXL compounds act through the inhibition of the sarco-endoplasmic reticulum calcium ATPase (SERCA). SERCA inhibition causes cell death through an increase in cytosolic calcium levels, ER stress, and triggering the unfolded protein response. The binding site of CXL compounds on SERCA and the identity of other cellular targets have been investigated through photoaffinity labeling with probes CXL039 and CXL037 respectively. Alterations in the synthesis of CXL compounds were also examined to improve the overall yield. Compounds that exhibit the same cytotoxicity profile as CXL compounds were explored through a cell based screen of natural products in HL60 and HL60 doxorubicin resistant cells.
  • Thumbnail Image
    Item
    Synergistic Effects Of Combining Therapeutic Radiation And ß-Lapachone Against Tumors
    (2013-12) Dos-Santos, Troy
    Understanding the mechanisms of the experimental anti-cancer drug β-Lapachone is crucial for optimizing its mode of action - especially when it is used in conjunction with other treatment regimens, namely therapeutic radiation, due to possible interactions. It is our aim to exploit the knowledge gained from studying the interaction between β-Lapachone and radiation for better tumor control. β-Lapachone is a novel anti-cancer compound that is activated intracellularly by the enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1), which is over-expressed in many cancer cells. It has been reported that concentrations of NQO1 can be further up-regulated by various cellular stressors including radiation. Therefore radiation potentiates β-Lapachone's cytotoxicity when radiation is used as a pre-treatment. Treating with β-Lapachone in fractionated radiation treatments, have been shown to suppress sub-lethal damage (SLD) repair of radiation damage. Therefore combined treatments of radiation and β-Lapachone have been observed to involve synergistic interactions based on two complementary actions: pretreatment of cancer cells with radiation to increase NQO1 which potentiate β-Lapachone's cytotoxicity and suppression of SLD repair by β-Lapachone post irradiation. In an attempt to illuminate important factors for designing an optimal treatment for solid tumor control, a deeper understanding of the interactions between the two treatments was needed, such as, the changes made in the cell cycle of several cell lines by various treatment combinations involving radiation and β-Lapachone, changes made in the concentrations of NQO1 pre/post-treatments involving β-Lapachone, and the impact of treatment on the tumor micro-environment in regards to in vivo tumor response to fractionated radiation in the presents of β-Lapachone. Our results shows a marked sensitization towards radiation of FSaII and A549 cells treated with β-Lapachone and a significant suppression of sub-lethal damage (SLD) repair. β- Lapachone's cytotoxicity appears to be agnostic towards cell cycle phase and hypoxic cells. β- Lapachone has also been shown to be effective in delaying growth of FSaII tumors grown in C3H mice when treated in a single β-Lapachone dose and a single fraction of radiation as opposed to its fractionated regimen analog, and so placing it as a candidate for steriotatic body radiation therapy (SBRT) and steriotatic radiosurgery (SRS) combined treatments.